Month: January 2017

Quantum Blue® Infliximab Assay Highlights

US: BÜHLMANN Quantum Blue® Infliximab is for Research Use Only in the US. Not to be used in diagnostic procedures. Canada: BÜHLMANN Quantum Blue® Infliximab: Health Canada License: 98838 Rapid, Simple, Accurate Quantitative Results BÜHLMANN’s Quantum Blue® Product line is designed with an innovative solution based on established lateral flow technology which utilizes highly specific monoclonal antibodies to capture

Connect with BUHLMANN Diagnostics Corp at CDDW 2017

Canadian Digestive Diseases Week (CDDW) 2017 BUHLMANN Diagnostics Corp Booth: #1032 Mar 03 – 06, 2017 LOCATION The Fairmont Banff Springs Banff, Alberta LEARN MORE Click & Contact CDDW 2017 BUHLMANN Team Connect with our team ahead of time, learn more about our Calprotectin Assays or schedule a meeting! COLLIN SHAW VP of Business Development

BÜHLMANN Laboratories AG (BL), based in Basel Switzerland, has been discovering, developing & manufacturing innovative chemistry and immunological in-vitro diagnostic (IVD) and research use only (RUO) assays for almost 50 years (circa 1976). As the United States commercial affiliate of BL, BUHLMANN Diagnostics Corp (BDC), based in Amherst, NH is committed to providing exceptional sales, support, and technical services to our clinical, discovery and basic science research laboratory customers.

Month: January 2017

Quantum Blue® Infliximab Assay Highlights

Connect with BUHLMANN Diagnostics Corp at CDDW 2017

ABOUT US

SOCIAL MEDIA

QUICK LINKS

CONTACT US